Keyword: solanezumab

8. Eli Lilly

Eli Lilly spent nearly a quarter of its income on R&D last year, putting it near the top of its peers in percentage terms, and saw some of that spend pay off—overall, however, last year was a mixed bag for the company’s research.

6. AstraZeneca

by Ben Adams

AstraZeneca had a pretty rough few years of R&D setbacks and failures up until 2012, when its former chief, David Brennan, was all but pushed out as a result. But things seem to have steadied somewhat since Pascal Soriot took the helm.

Analysts on amyloid thesis: It's not dead yet

by Ben Adams

Friday, December 9, 2016

Just a few weeks back, many were writing off the amyloid hypothesis in Alzheimer’s after Lilly posted top-line data showing its candidate failed a phase 3. Last night, however, Biogen released some fresh data for its drug aducanumab that, alongside some more detailed info from Lilly’s failed med, may just warrant another look.

Alzheimer’s biotech Alzheon to move once-failed drug into new PhIII

by Ben Adams

Monday, July 25, 2016

As the world’s top researchers working in Alzheimer’s disease descend into Toronto for the AAIC this week, all will be coming with a continued show of hope--despite the slew of late-stage failures for the disease over the past decade.